Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECURE: SB012 enema for active ulcerative colitis
2013-004599-36Phase 2Completed
- Sponsor
- sterna biologicals
- Start
- Feb 2014
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing SB012 enema with Placebo enema (2 arms). Primary endpoint: Change in Total Mayo score after 4 weeks of treatment. Started Feb 2014; status: completed.
02
Drugs
SB012
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-004599-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004599-36.